165 related articles for article (PubMed ID: 37324004)
1. Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule.
Grimaudo MS; Laffi A; Gennaro N; Fazio R; D'Orazio F; Samà L; Siracusano LV; Sicoli F; Renne SL; Santoro A; Bertuzzi AF
Front Oncol; 2023; 13():1190123. PubMed ID: 37324004
[TBL] [Abstract][Full Text] [Related]
2. Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study.
Nannini M; Rizzo A; Nigro MC; Vincenzi B; Mazzocca A; Grignani G; Merlini A; D'Ambrosio L; Tolomeo F; Badalamenti G; Incorvaia L; Bonasera A; Fumagalli E; Miliziano D; Ligorio F; Brunello A; Chiusole B; Gasperoni S; Novelli M; Pantaleo MA
ESMO Open; 2021 Aug; 6(4):100222. PubMed ID: 34352702
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
[TBL] [Abstract][Full Text] [Related]
4. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
[TBL] [Abstract][Full Text] [Related]
5. Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre.
Chamberlain F; Farag S; Williams-Sharkey C; Collingwood C; Chen L; Mansukhani S; Engelmann B; Al-Muderis O; Chauhan D; Thway K; Fisher C; Jones RL; Gennatas S; Benson C
Clin Sarcoma Res; 2020; 10():1. PubMed ID: 31911828
[TBL] [Abstract][Full Text] [Related]
6. Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice.
Nannini M; Nigro MC; Vincenzi B; Fumagalli E; Grignani G; D'Ambrosio L; Badalamenti G; Incorvaia L; Bracci R; Gasperoni S; Saponara M; Gatto L; Indio V; Astolfi A; Di Scioscio V; Casali PG; Tonini G; Aglietta M; Russo A; Biasco G; Pantaleo MA
Ther Adv Med Oncol; 2017 Dec; 9(12):731-739. PubMed ID: 29449894
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
[TBL] [Abstract][Full Text] [Related]
8. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
Rutkowski P; Stępniak J
Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
[TBL] [Abstract][Full Text] [Related]
9. Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors.
Ivanyi P; Eggers H; Hornig M; Kasper B; Heissner K; Kopp HG; Kirstein M; Ganser A; Grünwald V
Mol Clin Oncol; 2020 Dec; 13(6):72. PubMed ID: 33005406
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients.
Schvartsman G; Wagner MJ; Amini B; Zobniw CM; Trinh VA; Barbo AG; Lin HY; Wang WL; Conley AP; Ravi V; Araujo DM; Zarzour MA; Benjamin RS; Patel S; Somaiah N
Sci Rep; 2017 Aug; 7(1):9519. PubMed ID: 28842575
[TBL] [Abstract][Full Text] [Related]
12. Real-world experience of safety and effectiveness of regorafenib for treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and hepatocellular carcinoma: a post-marketing surveillance study in Korea.
Beom SH; Bae KB; Zang DY; Bae J; Hwang IG; Kang HJ; Woo IS; Shim BY; Bae BN; Cheon J; Oh SB; Ahn JB
J Cancer; 2022; 13(13):3396-3403. PubMed ID: 36313033
[No Abstract] [Full Text] [Related]
13. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of regorafenib in Japanese patients with advanced gastrointestinal stromal tumors.
Teranishi R; Takahashi T; Nishida T; Hirota S; Kurokawa Y; Saito T; Yamamoto K; Yamashita K; Tanaka K; Makino T; Motoori M; Omori T; Nakajima K; Eguchi H; Doki Y
Int J Clin Oncol; 2022 Jul; 27(7):1164-1172. PubMed ID: 35435530
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive Surgery may be beneficial for highly selected patients with Metastatic Gastrointestinal Stromal Tumors receiving Regorafenib facing Local Progression: A Case Controlled Study.
Yeh CN; Hu CH; Wang SY; Wu CE; Chen JS; Tsai CY; Hsu JT; Yeh TS
J Cancer; 2021; 12(11):3335-3343. PubMed ID: 33976743
[No Abstract] [Full Text] [Related]
17. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
[TBL] [Abstract][Full Text] [Related]
18. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
Zalcberg JR
Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
[TBL] [Abstract][Full Text] [Related]
19. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
